These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 28220519)

  • 1. Red blood cell concentrates treated with the amustaline (S-303) pathogen reduction system and stored for 35 days retain post-transfusion viability: results of a two-centre study.
    Cancelas JA; Gottschall JL; Rugg N; Graminske S; Schott MA; North A; Huang N; Mufti N; Erickson A; Rico S; Corash L
    Vox Sang; 2017 Apr; 112(3):210-218. PubMed ID: 28220519
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stored red blood cell viability is maintained after treatment with a second-generation S-303 pathogen inactivation process.
    Cancelas JA; Dumont LJ; Rugg N; Szczepiorkowski ZM; Herschel L; Siegel A; Pratt PG; Worsham DN; Erickson A; Propst M; North A; Sherman CD; Mufti NA; Reed WF; Corash L
    Transfusion; 2011 Nov; 51(11):2367-76. PubMed ID: 21569044
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Red blood cells treated with the amustaline (S-303) pathogen reduction system: a transfusion study in cardiac surgery.
    Brixner V; Kiessling AH; Madlener K; Müller MM; Leibacher J; Dombos S; Weber I; Pfeiffer HU; Geisen C; Schmidt M; Henschler R; North A; Huang N; Mufti N; Erickson A; Ernst C; Rico S; Benjamin RJ; Corash LM; Seifried E
    Transfusion; 2018 Apr; 58(4):905-916. PubMed ID: 29498049
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Viability of red cells prepared with S-303 pathogen inactivation treatment.
    Rios JA; Hambleton J; Viele M; Rugg N; Sindermann G; Greenwalt T; Wages D; Cook D; Corash L
    Transfusion; 2006 Oct; 46(10):1778-86. PubMed ID: 17002635
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Red blood cell in vitro quality and function is maintained after S-303 pathogen inactivation treatment.
    Winter KM; Johnson L; Kwok M; Vidovic D; Hyland RA; Mufti N; Erickson A; Marks DC
    Transfusion; 2014 Jul; 54(7):1798-807. PubMed ID: 24617658
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical safety assessment of pathogen reduced red blood cells treated with amustaline and glutathione.
    North AK; Mufti N; Sullivan T; Corash L
    Transfusion; 2020 Feb; 60(2):358-366. PubMed ID: 31930533
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pathogen inactivation of Dengue virus in red blood cells using amustaline and glutathione.
    Aubry M; Laughhunn A; Santa Maria F; Lanteri MC; Stassinopoulos A; Musso D
    Transfusion; 2017 Dec; 57(12):2888-2896. PubMed ID: 28921542
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Red blood cells derived from whole blood treated with riboflavin and ultraviolet light maintain adequate survival in vivo after 21 days of storage.
    Cancelas JA; Slichter SJ; Rugg N; Pratt PG; Nestheide S; Corson J; Pellham E; Huntington M; Goodrich RP
    Transfusion; 2017 May; 57(5):1218-1225. PubMed ID: 28369971
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inactivation of Plasmodium falciparum in whole blood using the amustaline and glutathione pathogen reduction technology.
    Sow C; Laughhunn A; Girard YA; Lanteri MC; Amar El Dusouqui S; Stassinopoulos A; Grellier P
    Transfusion; 2020 Apr; 60(4):799-805. PubMed ID: 32129497
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the efficacy and safety of amustaline/glutathione pathogen-reduced RBCs in complex cardiac surgery: the Red Cell Pathogen Inactivation (ReCePI) study-protocol for a phase 3, randomized, controlled trial.
    Snyder EL; Sekela ME; Welsby IJ; Toyoda Y; Alsammak M; Sodha NR; Beaver TM; Pelletier JPR; Gorham JD; McNeil JS; Sniecinski RM; Pearl RG; Nuttall GA; Sarode R; Reece TB; Kaplan A; Davenport RD; Ipe TS; Benharash P; Lopez-Plaza I; Gammon RR; Sadler P; Pitman JP; Liu K; Bentow S; Corash L; Mufti N; Varrone J; Benjamin RJ;
    Trials; 2023 Dec; 24(1):799. PubMed ID: 38082326
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Survival of red blood cells after transfusion: a comparison between red cells concentrates of different storage periods.
    Luten M; Roerdinkholder-Stoelwinder B; Schaap NP; de Grip WJ; Bos HJ; Bosman GJ
    Transfusion; 2008 Jul; 48(7):1478-85. PubMed ID: 18482180
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence of natural and acquired antibodies to amustaline/glutathione pathogen reduced red blood cells.
    Geisen C; North A; Becker L; Brixner V; von Goetz M; Corash L; Benjamin RJ; Mufti N; Seifried E
    Transfusion; 2020 Oct; 60(10):2389-2398. PubMed ID: 32692456
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amustaline (S-303) treatment inactivates high levels of Zika virus in red blood cell components.
    Laughhunn A; Santa Maria F; Broult J; Lanteri MC; Stassinopoulos A; Musso D; Aubry M
    Transfusion; 2017 Mar; 57(3pt2):779-789. PubMed ID: 28164306
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Robust inactivation of Plasmodium falciparum in red blood cell concentrates using amustaline and glutathione pathogen reduction.
    Sow C; Bouissou A; Girard YA; Singh GB; Bounaadja L; Payrat JM; Haas D; Isola H; Lanteri MC; Bringmann P; Grellier P
    Transfusion; 2022 May; 62(5):1073-1083. PubMed ID: 35385146
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic efficacy and safety of red blood cells treated with a chemical process (S-303) for pathogen inactivation: a Phase III clinical trial in cardiac surgery patients.
    Benjamin RJ; McCullough J; Mintz PD; Snyder E; Spotnitz WD; Rizzo RJ; Wages D; Lin JS; Wood L; Corash L; Conlan MG
    Transfusion; 2005 Nov; 45(11):1739-49. PubMed ID: 16271099
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Study of the Pharmacokinetic Properties and the In Vivo Kinetics of Erythrocytes Loaded With Dexamethasone Sodium Phosphate in Healthy Volunteers.
    Coker SA; Szczepiorkowski ZM; Siegel AH; Ferrari A; Mambrini G; Anand R; Hartman RD; Benatti L; Dumont LJ
    Transfus Med Rev; 2018 Apr; 32(2):102-110. PubMed ID: 29031409
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amustaline (S-303) treatment inactivates high levels of Chikungunya virus in red-blood-cell components.
    Aubry M; Laughhunn A; Santa Maria F; Lanteri MC; Stassinopoulos A; Musso D
    Vox Sang; 2018 Apr; 113(3):232-241. PubMed ID: 29314033
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Infusion of P-Capt prion-filtered red blood cell products demonstrate acceptable in vivo viability and no evidence of neoantigen formation.
    Cancelas JA; Rugg N; Pratt PG; Worsham DN; Pehta JC; Banks K; Davenport RD; Judd WJ
    Transfusion; 2011 Oct; 51(10):2228-36. PubMed ID: 21492178
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transfusion of stored red blood cells adhere in the rat microvasculature.
    Chin-Yee IH; Gray-Statchuk L; Milkovich S; Ellis CG
    Transfusion; 2009 Nov; 49(11):2304-10. PubMed ID: 19624601
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Amustaline-glutathione pathogen-reduced red blood cell concentrates for transfusion-dependent thalassaemia.
    Aydinok Y; Piga A; Origa R; Mufti N; Erickson A; North A; Waldhaus K; Ernst C; Lin JS; Huang N; Benjamin RJ; Corash L
    Br J Haematol; 2019 Aug; 186(4):625-636. PubMed ID: 31148155
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.